Pfizer Inc. (NYSE: PFE)’s stock price has decreased by -0.43 compared to its previous closing price of 27.65. However, the company has seen a -3.67% decrease in its stock price over the last five trading sessions. fool.com reported 2024-06-15 that Pfizer stock has been beaten down so far that it offers a dividend yield above 6% at recent prices. Bristol Myers Squibb has been trading for the low multiple of about 7 times trailing free cash flow.
Is It Worth Investing in Pfizer Inc. (NYSE: PFE) Right Now?
The 36-month beta value for PFE is also noteworthy at 0.67. There are mixed opinions on the stock, with 11 analysts rating it as a “buy,” 1 rating it as “overweight,” 9 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PFE is 5.66B, and at present, short sellers hold a 1.34% of that float. The average trading volume of PFE on June 17, 2024 was 38.83M shares.
PFE’s Market Performance
PFE’s stock has seen a -3.67% decrease for the week, with a -4.48% drop in the past month and a -1.47% fall in the past quarter. The volatility ratio for the week is 2.28%, and the volatility levels for the past 30 days are at 2.06% for Pfizer Inc. The simple moving average for the last 20 days is -3.73% for PFE stock, with a simple moving average of -5.66% for the last 200 days.
Analysts’ Opinion of PFE
Guggenheim, on the other hand, stated in their research note that they expect to see PFE reach a price target of $36. The rating they have provided for PFE stocks is “Buy” according to the report published on February 23rd, 2024.
TD Cowen gave a rating of “Market Perform” to PFE, setting the target price at $32 in the report published on January 04th of the current year.
PFE Trading at 0.11% from the 50-Day Moving Average
After a stumble in the market that brought PFE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.79% of loss for the given period.
Volatility was left at 2.06%, however, over the last 30 days, the volatility rate increased by 2.28%, as shares sank -4.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.30% upper at present.
During the last 5 trading sessions, PFE fell by -3.67%, which changed the moving average for the period of 200-days by -23.85% in comparison to the 20-day moving average, which settled at $28.53. In addition, Pfizer Inc. saw -4.38% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PFE starting from Gottlieb Scott, who purchase 3,000 shares at the price of $26.47 back on Dec 15 ’23. After this action, Gottlieb Scott now owns 9,000 shares of Pfizer Inc., valued at $79,401 using the latest closing price.
Stock Fundamentals for PFE
Current profitability levels for the company are sitting at:
- 0.03 for the present operating margin
- 0.49 for the gross margin
The net margin for Pfizer Inc. stands at -0.01. The total capital return value is set at 0.01. Equity return is now at value -0.30, with -0.14 for asset returns.
Based on Pfizer Inc. (PFE), the company’s capital structure generated 0.43 points at debt to capital in total, while cash flow to debt ratio is standing at 0.12. The debt to equity ratio resting at 0.75. The interest coverage ratio of the stock is 0.66.
Currently, EBITDA for the company is 10.53 billion with net debt to EBITDA at 8.27. When we switch over and look at the enterprise to sales, we see a ratio of 4.08. The receivables turnover for the company is 5.01for trailing twelve months and the total asset turnover is 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.05.
Conclusion
In summary, Pfizer Inc. (PFE) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
